• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Danimer Scientific Announces Second Quarter 2024 Results

    8/8/24 4:01:00 PM ET
    $DNMR
    Major Chemicals
    Industrials
    Get the next $DNMR alert in real time by email

    --Additional Resin Orders to Support 20-Million Pound Cutlery Award --

    -- Company Forecasting Annualized PHA Revenues to More Than Triple by End of Q2 2025 --

    -- Pro-Rata Warrant Dividend Transaction Provides Balance Sheet Deleveraging Opportunity --

    Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its second quarter ended June 30, 2024.

    Stephen E. Croskrey, Chief Executive Officer of Danimer, commented, "We completed the second quarter in line with our expectations considering the temporary impact of Starbucks' reapportionment of their Nodax-based straw business between our converter partners. We believe these headwinds will continue into the third quarter, but at a lesser degree than experienced during the second quarter. It is important to reiterate that we have retained 100% of this business, and we remain on track to continue to grow our PHA business during 2024."

    Mr. Croskrey continued, "Our 20-million-pound cutlery award continues to progress. Our converter partners have received initial molds for testing, and some have purchased new injection molding equipment. To date, we have received four commercial orders, with one order having been delivered and the others expected to ship by the end of this month. We expect this award to reach full run rate in mid-2025."

    Mr. Croskrey concluded, "Our recently completed pro-rata warrant dividend transaction has provided a potential new avenue to deleverage our balance sheet, strengthen our capital structure and maximize stockholder value. We are pleased that we have been able to retire $6.1 million of our 3.25% convertible notes as of the date of this release."

    Second Quarter 2024 Financial Highlights:

    • Revenues of $7.6 million in the second quarter of 2024 were down by $5.3 million compared to revenue of $12.9 million in the second quarter of 2023. PHA revenue of $5.9 million decreased by $2.5 million in the quarter as compared with the prior year quarter. This was primarily due to the reapportionment of Starbucks' straw business which led to excess inventory in the channel with the Company's converter partners. PLA revenue of $1.4 million decreased by $2.4 million quarter-over-quarter, primarily due to a loss of orders from customers affected by the conflict in Ukraine.
    • Gross profit of $(6.9) million was in line with $(6.6) million in the second quarter of 2023. Adjusted gross profit was $(1.8) million compared to $(1.6) million in the second quarter of 2023.
    • Adjusted EBITDA was $(9.9) million in the second quarter of 2024 which improved as compared to $(10.2) million in the second quarter of 2023.

    Capital Structure

    At June 30, 2024, the Company reported total debt outstanding of $393.9 million, which included approximately $45.7 million dollars of low-interest New Markets Tax Credit loans that the Company expects will be forgiven beginning in 2026.

    As previously disclosed, on April 19, 2024, the Company entered into a $20 million asset-based lending agreement (ABL) revolving credit facility that is secured primarily by its accounts receivable and inventory, subject to borrowing base limitations. The Company had borrowed $5.2 million against this facility as of June 30, 2024 and continues to explore additional avenues to manage its liquidity position and enable it to maintain strategic and operational flexibility as it executes its growth strategy.

    On July 12, 2024, the Company distributed warrants to stockholders of record as of May 13, 2024, who received one warrant ("Dividend Warrant") for each three shares of common stock. Holders of the Company's 3.250% convertible senior notes and its pre-funded common stock purchase warrants as of the record date also received Dividend Warrants on a pass-through basis. For additional information on the Dividend Warrant, please see the FAQs on the Investor Relations section of the Company's website at https://ir.danimerscientific.com/.

    Outlook

    The Company reported second quarter results that were consistent with its expectations including the impact of the reapportionment related to the Starbucks straw resin business. The Company anticipates that these headwinds will continue into the third quarter but with a much lower impact compared to the second quarter. As such, the Company is making the following adjustments to annual guidance:

    • Full-year Adjusted EBITDA is now expected to be in the range of $(30) million to $(35) million.
    • Full-year capital expenditures are anticipated to remain in the previously disclosed range of $8 million to $10 million, which will support existing commitments related to the Bainbridge greenfield facility, maintenance expenditures and other capital projects.
    • Year-end liquidity, which comprises unrestricted cash and projected availability under the revolving credit facility, will be in the range of $15 million to $20 million.

    Additionally, the Company is now forecasting annualized PHA revenues to more than triple by the end of the second quarter of 2025, based solely on demand from existing customer relationships and their indicated volumes, including the aforementioned 20-million-pound cutlery award.

    Webcast, Conference Call and 10-Q Filing

    The Company will host a webcast and conference call today, Thursday August 8, 2024, at 4:30 p.m. Eastern time to review second quarter 2024 results, discuss recent events and conduct a question-and-answer session. The live webcast of the conference call can be accessed on the Investor Relations section of the Company's website at https://ir.danimerscientific.com. For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-800-717-1738 or 1-646-307-1865, respectively. Upon dialing in, please request to join the Danimer Scientific Second Quarter 2024 Earnings Conference Call. The archived webcast will be available for replay on the Company's website after the call.

    About Danimer Scientific

    Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer's technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit https://danimerscientific.com.

    Forward‐Looking Statements

    Please note that this press release may use words such as "appears," "anticipates," "believes," "plans," "expects," "intends," "future," and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding expectations for the full year 2024 capital expenditures, Adjusted EBITDA and liquidity, and statements regarding expected PHA revenue growth, as well as statements regarding the exercise of Dividend Warrants using 3.250% convertible senior notes to pay the exercise price. Forward-looking statements are made based on expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. The Company cautions that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company's exposure to product liability or product warranty claims and other loss contingencies; the outcomes of any litigation matters; the impact on our business, operations and financial results from the ongoing conflicts in Ukraine and the Middle East; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release and speak only as of the date hereof. The Company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

    Danimer Scientific, Inc.

    Condensed Consolidated Balance Sheets

     

    June 30,

     

    December 31,

    (in thousands, except share and per share data)

     

    2024

     

     

     

    2023

     

    Assets:
    Current assets:
    Cash and cash equivalents

    $

    40,254

     

    $

    59,170

     

    Accounts receivable, net

     

    10,928

     

     

    15,227

     

    Other receivables, net

     

    580

     

     

    652

     

    Inventories, net

     

    26,277

     

     

    25,270

     

    Prepaid expenses and other current assets

     

    5,907

     

     

    4,714

     

    Contract assets, net

     

    2,928

     

     

    3,005

     

    Total current assets

     

    86,874

     

     

    108,038

     

     
    Property, plant and equipment, net

     

    434,257

     

     

    445,153

     

    Intangible assets, net

     

    76,415

     

     

    77,790

     

    Right-of-use assets

     

    19,163

     

     

    19,160

     

    Leverage loans receivable

     

    31,446

     

     

    31,446

     

    Restricted cash

     

    14,167

     

     

    14,334

     

    Other assets

     

    4,218

     

     

    2,210

     

    Total assets

    $

    666,540

     

    $

    698,131

     

     
    Liabilities and Stockholders' Equity:
    Current liabilities:
    Accounts payable

    $

    2,880

     

    $

    5,292

     

    Accrued liabilities

     

    4,781

     

     

    4,726

     

    Unearned revenue and contract liabilities

     

    850

     

     

    1,000

     

    Current portion of lease liability

     

    3,723

     

     

    3,337

     

    Current portion of long-term debt, net

     

    6,976

     

     

    1,368

     

    Total current liabilities

     

    19,210

     

     

    15,723

     

     
    Long-term lease liability, net

     

    21,461

     

     

    21,927

     

    Long-term debt, net

     

    386,910

     

     

    381,436

     

    Warrant liability

     

    3,914

     

     

    5

     

    Other long-term liabilities

     

    1,017

     

     

    1,020

     

    Total liabilities

    $

    432,512

     

    $

    420,111

     

     
    Stockholders' equity:
    Common stock, $0.0001 par value; 200,000,000 shares authorized: 116,608,522 and 102,832,103 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively

    $

    12

     

    $

    10

     

    Additional paid-in capital

     

    738,061

     

     

    732,131

     

    Accumulated deficit

     

    (504,045

    )

     

    (454,121

    )

    Total stockholders' equity

     

    234,028

     

     

    278,020

     

    Total liabilities and stockholders' equity

    $

    666,540

     

    $

    698,131

     

     

    Danimer Scientific, Inc.

    Condensed Consolidated Statements of Operations

     

    Three Months Ended June 30,

    Six Months Ended June 30,

    (in thousands, except share and per share data)

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

     
    Revenue:
    Products

    $

    7,246

     

    $

    12,174

     

    $

    17,201

     

    $

    23,270

     

    Services

     

    382

     

     

    691

     

     

    651

     

     

    1,521

     

    Total revenue

     

    7,628

     

     

    12,865

     

     

    17,852

     

     

    24,791

     

     
    Costs and expenses:
    Cost of revenue

     

    14,531

     

     

    19,433

     

     

    31,066

     

     

    37,642

     

    Selling, general and administrative

     

    6,752

     

     

    16,844

     

     

    13,621

     

     

    35,543

     

    Research and development

     

    5,109

     

     

    7,709

     

     

    10,451

     

     

    14,784

     

    Loss on sale of assets

     

    565

     

     

    -

     

     

    565

     

     

    170

     

    Total costs and expenses

     

    26,957

     

     

    43,986

     

     

    55,703

     

     

    88,139

     

    Loss from operations

     

    (19,329

    )

     

    (31,121

    )

     

    (37,851

    )

     

    (63,348

    )

    Nonoperating income (expense)
    Gain (loss) on remeasurement of warrants

     

    5,742

     

     

    1,083

     

     

    5,841

     

     

    (33

    )

    Interest, net

     

    (9,072

    )

     

    (9,162

    )

     

    (17,910

    )

     

    (12,548

    )

    Loss on loan extinguishment

     

    -

     

     

    (102

    )

     

    -

     

     

    (102

    )

    Total nonoperating expense:

     

    (3,330

    )

     

    (8,181

    )

     

    (12,069

    )

     

    (12,683

    )

    Loss before income taxes

     

    (22,659

    )

     

    (39,302

    )

     

    (49,920

    )

     

    (76,031

    )

    Income taxes

     

    (2

    )

     

    61

     

     

    (4

    )

     

    151

     

    Net loss

    $

    (22,661

    )

    $

    (39,241

    )

    $

    (49,924

    )

    $

    (75,880

    )

     
    Basic net loss per share

    $

    (0.19

    )

    $

    (0.38

    )

    $

    (0.45

    )

    $

    (0.74

    )

     
    Weighted average shares outstanding

     

    116,465,086

     

     

    101,938,376

     

     

    110,114,660

     

     

    101,917,585

     

     

    Danimer Scientific, Inc.

    Condensed Consolidated Statements of Cash Flows

     

     

     

    Six Months Ended

     

     

    June 30,

    (in thousands)

     

     

    2024

     

     

     

    2023

     

    Cash flows from operating activities:
    Net loss

    $

    (49,924

    )

    $

    (75,880

    )

    Adjustments to reconcile net loss to net cash used in operating activities:
    Depreciation and amortization

     

    14,969

     

     

    14,752

     

    (Gain) loss on remeasurement of warrants

     

    (5,841

    )

     

    33

     

    Amortization of debt issuance costs

     

    5,821

     

     

    3,485

     

    Stock-based compensation

     

    1,169

     

     

    27,974

     

    Warrant issuance costs

     

    867

     

     

    -

     

    Loss on disposal of assets

     

    565

     

     

    170

     

    Accounts receivable reserves

     

    437

     

     

    (948

    )

    Inventory reserves

     

    (313

    )

     

    464

     

    Amortization of right-of-use assets and lease liability

     

    (83

    )

     

    (237

    )

    Deferred income taxes

     

    -

     

     

    (155

    )

    Other

     

    -

     

     

    1,046

     

    Changes in operating assets and liabilities:
    Accounts receivable

     

    3,863

     

     

    5,939

     

    Other receivables

     

    74

     

     

    38

     

    Inventories, net

     

    (694

    )

     

    2,383

     

    Prepaid expenses and other current assets

     

    (751

    )

     

    1,130

     

    Contract assets

     

    (185

    )

     

    (959

    )

    Other assets

     

    70

     

     

    (120

    )

    Accounts payable

     

    (2,078

    )

     

    (2,377

    )

    Accrued liabilities

     

    227

     

     

    600

     

    Other long-term liabilities

     

    (4

    )

     

    636

     

    Unearned revenue and contract liabilities

     

    (150

    )

     

    875

     

    Net cash used in operating activities

     

    (31,961

    )

     

    (21,151

    )

    Cash flows from investing activities:
    Purchases of property, plant and equipment and intangible assets

     

    (3,770

    )

     

    (23,041

    )

    Net cash used in investing activities

     

    (3,770

    )

     

    (23,041

    )

    Cash flows from financing activities:

    Proceeds from issuance of common warrants, net of issuance costs

     

    8,883

     

     

    -

     

    Proceeds from issuance of common stock, net of issuance costs

     

    4,658

     

     

    -

     

    Proceeds from long-term debt

     

    11,326

     

     

    130,000

     

    Principal payments on long-term debt

     

    (7,227

    )

     

    (11,744

    )

    Cash paid for debt issuance costs

     

    (1,095

    )

     

    (33,295

    )

    Proceeds from employee stock purchase plan

     

    118

     

     

    129

     

    Employee taxes related to stock-based compensation

     

    (15

    )

     

    (61

    )

    Net cash provided by financing activities

     

    16,648

     

     

    85,029

     

    Net (decrease) increase in cash and cash equivalents and restricted cash

     

    (19,083

    )

     

    40,837

     

    Cash and cash equivalents and restricted cash-beginning of period

     

    73,504

     

     

    64,401

     

    Cash and cash equivalents and restricted cash-end of period

    $

    54,421

     

    $

    105,238

     

     

    Non-GAAP Financial Measures

    This press release includes the non-GAAP financial measures "Adjusted EBITDA", "Adjusted gross profit" and "Adjusted gross margin". Danimer management views these metrics as a useful way to look at the performance of its operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.

    Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of warrants, stock-based compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments and impairment of goodwill; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer's business, as described below.

    Adjusted gross profit is defined as gross profit plus depreciation, stock-based compensation and other nonrecurring items.

    Adjusted gross margin is defined as adjusted gross profit divided by total revenue.

    Danimer believes that each of Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin is useful to investors in evaluating the Company's performance because each measure considers the performance of the Company's operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.

    Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer's industry may define Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin exclude certain financial information that some may consider important in evaluating Danimer's performance.

    Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer's operating results. Because GAAP financial measures on a forward-looking basis are not accessible, and reconciling information is not available without unreasonable effort, reconciliations to GAAP financial measures are not provided for forward-looking non-GAAP measures. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

    Danimer Scientific, Inc.

    Reconciliation of Adjusted EBITDA to Net Loss (Unaudited)

     

    Three Months Ended June 30,

     

    2024

     

     

    2023

     

    (in thousands)
    Net loss

    $

    (22,661

    )

    $

    (39,241

    )

    Interest, net

     

    9,072

     

     

    9,162

     

    Depreciation and amortization

     

    7,438

     

     

    7,173

     

    (Gain) loss on remeasurement of warrants

     

    (5,742

    )

     

    (1,083

    )

    Transaction and other related

     

    807

     

     

    -

     

    Strategic reorganization and related

     

    738

     

     

    28

     

    Litigation and other legal related

     

    280

     

     

    37

     

    Stock-based compensation

     

    199

     

     

    13,666

     

    Income taxes

     

    2

     

     

    (61

    )

    Loss on extinguishment of debt

     

    -

     

     

    102

     

    Adjusted EBITDA

    $

    (9,867

    )

    $

    (10,217

    )

     

    Reconciliation of Adjusted Gross Profit to Gross Profit (Unaudited)

     

    Three Months Ended June 30,

     

    2024

     

     

    2023

     

    (in thousands)
    Total revenue

    $

    7,628

     

    $

    12,865

     

    Cost of revenue

     

    14,531

     

     

    19,433

     

    Gross profit

     

    (6,903

    )

     

    (6,568

    )

    Depreciation

     

    5,105

     

     

    4,934

     

    Stock-based compensation

     

    3

     

     

    2

     

    Adjusted gross profit

    $

    (1,795

    )

    $

    (1,632

    )

     
    Adjusted gross margin

     

    (23.5

    %)

     

    (12.7

    %)

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240808243882/en/

    Get the next $DNMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNMR

    DatePrice TargetRatingAnalyst
    11/21/2024$40.00 → $5.50Hold
    TD Cowen
    11/20/2024$40.00 → $4.00Neutral → Underweight
    Piper Sandler
    8/13/2024$2.00 → $1.00Buy → Hold
    TD Cowen
    5/22/2024$1.30 → $0.80Buy → Hold
    Jefferies
    4/9/2024$3.50 → $1.25Overweight → Neutral
    Piper Sandler
    10/12/2022$4.50Overweight
    Piper Sandler
    9/23/2021$21.00Outperform
    Cowen
    More analyst ratings

    $DNMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace

      –Dividend warrants continue to trade on OTCQX marketplace under "DNMRW"– Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange ("NYSE") suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the Company did not meet the continued listing standard that requires listed companies to maintain a

      12/31/24 8:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Takes Action to Strengthen Capital Structure

      Announces Issuance of $11,250,000 Super Senior Secured Promissory Note Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that the Company issued a super senior secured promissory note (the "Secured Loan") in an aggregate principal amount of $11,250,000 to certain lenders under its existing term loan financing agreement, as well as certain additional lenders. The Secured Loan provides for $11,250,000 gross proceeds, less fees and expenses. The Secured Loan has a two-year maturity and accrues interest at 15.0% per annum, which interest is payab

      12/17/24 4:15:00 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • TerraNova Capital Equities announces three transactions totaling $45 Million

      NEW YORK, Nov. 20, 2024 /PRNewswire/ -- TerraNova Capital Equities, inc. (TerraNova), a leading financial advisory firm, is pleased to announce that its Structure Finance Group acted as sole advisor on three recent transactions: TerraNova Structured Finance Group acted as the sole advisor to Danimer Scientific, Inc. (NYSE:DNMR) on a $20 Million revolving credit facility. TerraNova is pleased to announce its role as the exclusive advisor to Danimer Scientific in securing a strategic ABL agreement with Mountain Ridge Capital.  This $20 million facility, collateralized by the Com

      11/20/24 10:30:00 AM ET
      $DNMR
      $INUV
      Major Chemicals
      Industrials
      Advertising
      Consumer Discretionary

    $DNMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hendrix Richard J bought $93,395 worth of shares (100,000 units at $0.93) (SEC Form 4)

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      11/28/23 5:35:32 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    SEC Filings

    See more
    • Danimer Scientific Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Danimer Scientific, Inc. (0001779020) (Filer)

      3/18/25 5:00:42 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Danimer Scientific, Inc. (0001779020) (Filer)

      2/28/25 5:00:09 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Danimer Scientific Inc.

      SCHEDULE 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

      2/14/25 5:41:32 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danimer Scientific Announces New Directors

      Dr. David Moody and Richard Altice to Join the Danimer Board Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading, next-generation bioplastics company focused on the production of biodegradable materials, is pleased to announce that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer's Board of Directors. Dr. Moody's appointment is effective immediately, and Mr. Altice's appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the me

      1/18/24 4:30:00 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Appoints Stephen Martin as Chief Legal Officer and Corporate Secretary

      Martin, a Duke University graduate and former Air Force officer, brings experience managing the legal affairs of publicly traded companies Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of biodegradable materials, today announced it has appointed Stephen Martin as Chief Legal Officer and Corporate Secretary. In this role, Martin will manage a wide range of legal matters across the company as Danimer continues to expand its manufacturing capacity to meet demand in the fast-growing bioplastics market. Martin joins Danimer from Kaman Distribution Group, a leading national distributor o

      9/20/22 8:30:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Appoints Anthony Austin as Chief Human Resource Officer

      Austin brings more than 30 years of human resources leadership experience with PepsiCo, Delta Air Lines, Winn-Dixie and others Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of biodegradable materials, today announced it has appointed Anthony Austin as Chief Human Resource Officer. In this role, Austin will focus on building best-in-class HR processes to strategically support the Company's growth as it continues to expand its manufacturing capacity. Austin joins Danimer from Bedrock Manufacturing Co., the parent company of Shinola, a luxury watch, leather and jewelry manufacturer an

      4/20/22 8:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Hajost Michael A converted options into 859 shares and covered exercise/tax liability with 301 shares, increasing direct ownership by 31% to 2,334 units (SEC Form 4)

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      2/10/25 4:30:05 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Director Moody David Jesse converted options into 646 shares (SEC Form 4)

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      1/21/25 4:30:10 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • SEC Form 4 filed by Director Croskrey Stephen

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      1/3/25 4:05:07 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Danimer Scientific Inc.

      SC 13G - Danimer Scientific, Inc. (0001779020) (Subject)

      11/14/24 3:28:09 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Danimer Scientific Inc.

      SC 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

      7/8/24 4:36:39 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Danimer Scientific Inc. (Amendment)

      SC 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

      1/29/24 5:25:54 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Financials

    Live finance-specific insights

    See more
    • Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace

      –Dividend warrants continue to trade on OTCQX marketplace under "DNMRW"– Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange ("NYSE") suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the Company did not meet the continued listing standard that requires listed companies to maintain a

      12/31/24 8:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Announces Third Quarter 2024 Results

      --Additional Resin Orders and Deliveries Continue to Support 20-Million Pound Cutlery Award –- -- 100% Compostable Skittles® Bag Made with Nodax® PHA Featured at NFL Game -- Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its third quarter ended September 30, 2024. Richard N. Altice, Interim Chief Executive Officer of Danimer, commented, "We completed the third quarter in line with our expectations considering the temporary impact of Starbucks' reapportionment of their Nodax-based straw business between our convert

      11/19/24 8:30:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Announces Release Date for Third Quarter 2024 Results

      Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 19, 2024. A webcast and conference call will be held that same day at 10:00 a.m. Eastern Time to review the Company's third quarter results. The webcast of the conference will be accessible on the Investor Relations section of the Company's website at https://ir.danimerscientific.com. For those unable to access the webcast, the conference call will be accessible domestically o

      11/14/24 9:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen reiterated coverage on Danimer Scientific with a new price target

      TD Cowen reiterated coverage of Danimer Scientific with a rating of Hold and set a new price target of $5.50 from $40.00 previously

      11/21/24 8:09:13 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Danimer Scientific from Neutral to Underweight and set a new price target of $4.00 from $40.00 previously

      11/20/24 9:49:17 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific downgraded by TD Cowen with a new price target

      TD Cowen downgraded Danimer Scientific from Buy to Hold and set a new price target of $1.00 from $2.00 previously

      8/13/24 7:29:01 AM ET
      $DNMR
      Major Chemicals
      Industrials